This research article investigates how a single oncolytic virus treatment can trigger a robust and lasting immune response in patients with recurrent glioblastoma. Using advanced spatial technologies like CODEX and Xenium, the authors demonstrate that the therapy causes T cells to infiltrate deeply into tumor regions, where they remain active for months or even years. The study highlights that the expansion of pre-existing T cell clones is a key driver of clinical success, directly correlating with improved patient survival outcomes. Notably, the remaining viral elements were found only in dead tissue, suggesting that the long-term anti-tumor activity is sustained by the immune system rather than the virus itself. However, the researchers also identified hypoxic tumor regions as significant barriers that exclude T cells and contribute to treatment resistance. These findings offer a precise spatial map of how immunotherapy can overcome the characteristically "cold" environment of brain cancer.

References:

• Meylan M, Tian Y, Wu L, et al. Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial[J]. Cell, 2026.